Can a stimulant drug stop Binge-Eating relapse? new study tests LDX
NCT ID NCT03926052
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This study tested whether the drug lisdexamfetamine (LDX) can help adults with binge-eating disorder and obesity avoid relapse. 61 participants who initially responded to treatment were randomly assigned to receive LDX or a placebo for 12 weeks. The main goal was to see if LDX reduced the number of binge-eating episodes compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale Department of Psychiatry
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lisdexamfetamine (LDX)
What this could lead to
If it works, this could provide a medication option to help people with binge-eating disorder maintain control and avoid relapse after initial treatment.
What could go wrong
This is a small, completed Phase 3 trial with only 61 participants, so results may not apply to everyone. LDX is a stimulant and can have side effects like increased heart rate or risk of misuse.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.